Phan Hanna, Nahata Milap C
College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
Paediatr Drugs. 2008;10(1):49-69. doi: 10.2165/00148581-200810010-00006.
Dexmedetomidine is being used off-label as an adjunctive agent for sedation and analgesia in pediatric patients in the critical care unit and for sedation during non-invasive procedures in radiology. It also has a potential role as part of anesthesia care to prevent emergence delirium and postanesthesia shivering. Dexmedetomidine is currently approved by the US FDA for sedation only in adults undergoing mechanical ventilation for <24 hours. Pediatric experiences in the literature are in the form of small studies and case reports. In patients sedated for mechanical ventilation and/or opioid/benzodiazepine withdrawal, the loading dose ranged from 0.5 to 1 microg/kg and was usually administered over 10 minutes, although not all patients received loading doses. This patient group also received a continuous infusion at rates ranging from 0.2 to 2 microg/kg/h, with higher rates used in burn patients and those with withdrawal following > or =24 hours of opioid/benzodiazepine infusion. The dexmedetomidine dosage used for anesthesia and sedation during non-invasive procedures, such as radiologic studies, ranged from a loading dose of 1-2 microg/kg followed by a continuous infusion at 0.5-1.14 microg/kg/h, with most patients spontaneously breathing. For invasive procedures, such as awake craniotomy or cardiac catheterization, dosage ranged from a loading dose of 0.15 to 1 microg/kg followed by a continuous infusion at 0.1-2 microg/kg/h. Adverse hemodynamic and respiratory effects were minimal; the agent was well tolerated in most patients. The efficacy of dexmedetomidine varied depending on the clinical situation: efficacy was greatest during non-invasive procedures, such as magnetic resonance imaging (MRI), and lowest during invasive procedures, such as cardiac catheterization. Dexmedetomidine may be useful in pediatric patients for sedation in a variety of clinical situations. The literature suggests potential use of dexmedetomidine as an adjunctive agent to other sedatives during mechanical ventilation and opioid/benzodiazepine withdrawal. In addition, because of its minimal respiratory effects, dexmedetomidine has also been used as a single agent for sedation during non-invasive procedures such as MRI. However, additional studies in pediatric patients are warranted to further evaluate its safety and efficacy in all age ranges.
右美托咪定正在超适应症用于重症监护病房儿科患者的镇静和镇痛辅助用药,以及放射科无创检查期间的镇静。它还可能作为麻醉护理的一部分,用于预防苏醒期谵妄和术后寒战。右美托咪定目前仅被美国食品药品监督管理局批准用于接受机械通气时间小于24小时的成人镇静。文献中的儿科经验多为小型研究和病例报告。在因机械通气和/或阿片类药物/苯二氮䓬类药物戒断而接受镇静的患者中,负荷剂量为0.5至1微克/千克,通常在10分钟内给药,不过并非所有患者都接受负荷剂量。该患者群体还接受了0.2至2微克/千克/小时的持续输注,烧伤患者以及接受阿片类药物/苯二氮䓬类药物输注≥24小时后出现戒断症状的患者使用的输注速率更高。在诸如放射学检查等无创检查期间用于麻醉和镇静的右美托咪定剂量,负荷剂量为1 - 2微克/千克,随后以0.5 - 1.14微克/千克/小时的速率持续输注,大多数患者自主呼吸。对于诸如清醒开颅手术或心导管插入术等侵入性操作,剂量范围为负荷剂量0.15至1微克/千克,随后以0.1 - 2微克/千克/小时的速率持续输注。不良血流动力学和呼吸效应极小;大多数患者对该药物耐受性良好。右美托咪定的疗效因临床情况而异:在诸如磁共振成像(MRI)等无创检查期间疗效最佳,而在诸如心导管插入术等侵入性操作期间疗效最差。右美托咪定在儿科患者的各种临床情况下用于镇静可能是有用的。文献表明右美托咪定在机械通气和阿片类药物/苯二氮䓬类药物戒断期间可能作为其他镇静剂的辅助药物使用。此外,由于其对呼吸的影响极小,右美托咪定也已被用作诸如MRI等无创检查期间的单一镇静剂。然而,有必要在儿科患者中进行更多研究,以进一步评估其在所有年龄段的安全性和疗效。